newsfilter
← Latest News
GlobeNewswire·

Silexion Therapeutics Announces 1-for-24 Reverse Share Split

  • Silexion Therapeutics Corp. announced a 1-for-24 reverse share split effective after market close on November 10, 2026.
  • Trading on a split-adjusted basis begins at market open on November 11, 2026, under the existing ticker symbol "SLXN."
  • The new CUSIP number for post-split shares trading on November 11, 2026, is G1281K163.
  • Every 24 ordinary shares will be combined into one share, with the par value increasing from $0.135 to $3.24 per share.
  • No fractional shares will be issued, but DTC participants entitled to fractions will receive a rounded-up whole share.
  • The primary objective of the split is to regain compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2).
  • CEO Ilan Hadar stated the move aims to reduce volatility, broaden the investor base, support equity financings, & aid clinical progress for SIL204.
  • Shareholders holding shares in book-entry form or through brokers do not need to take any action as adjustments occur automatically.
  • Silexion is advancing its lead candidate SIL204 through a Phase 2/3 trial for locally advanced pancreatic cancer, having dosed its first patient in September 2026.
  • The company is a clinical-stage biotech focused on RNA interference therapies for KRAS-driven cancers.
Company
Silexion Therapeutics Corp
Keywords
Nasdaq:SLXN, Silexion Therapeutics Corp, NASDAQ:SLXN, SLXN, Silexion Therapeutics